PHVS Company Profile and Key Details

Pharvaris N.V. trades at a P/E ratio of -10.1, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 7.9 trading at moderately above to book value. The P/FCF stands at -13.47, also below market averages.

Pharvaris N.V. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.64. This means the shares are trading above this model’s fair value.

Short-term trend indicators are bearishly aligned (SMA20 2.94%, SMA50 5.84%, SMA200 23.1%). The stock’s 14-day RSI is 56.74 (neutral), while the ATR of 1.45 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -6.03% below its high and over 143.27% above its low. Average 10-day trading volume of 209.02 thousand shares is below the 3-month average of 318.83 thousand, indicating normal recent market interest.

Pharvaris N.V. generated EPS of -$3.22 over the past year. Five-year average earnings growth is -7.73%. Wall Street analysts project EPS growth of 3.74% annually over the next five years. The latest quarter delivered EPS of -$0.68. The next quarter is forecast at -$0.73. Next year's EPS is expected at $4.06. Analyst sentiment is bullish. Analyst rating data shows there are 10 Strong Buy ratings, 5 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $74.00 to $27.00. The high target offers 124.24% upside. The low target suggests -18.18% downside. The mean target is $47.47. This offers 43.85% upside. Pharvaris N.V. earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by -17.06%. The prior quarter beat by 18.34%. Over the last six quarters, Apple has recorded several small beats. These include 28.79% in November 13, 2024.

Pharvaris N.V. has 64.30 million shares outstanding. The public float is 37.11 million shares, elevated short interest at 0.76% of float. This equals 404.97 thousand shares. The short ratio is 3.54 days. Institutional investors hold 90.81% of the float. Insiders own 6.14%. Schikan Johannes Gerardus Christiaan Petrus holds 355.17 thousand shares, Modig Berndt has 135.21 thousand shares and Nassif David W. has 120.30 thousand shares. Over the past six months, insider transactions show net selling. They sold 127.84 thousand shares across 26 transactions.

Our AI price prediction model suggests that Pharvaris N.V. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.48%, with price expected at $34.48 by July 06, 2026, within a range of $33.55 to $35.42 3-Month Outlook: Projected rise of 32.67%, reaching $43.78 by September 16, 2026, with a range of $43.12 to $44.38. 1-Year Outlook: Projected gain of 3.24%, with price at $34.07 by June 22, 2027, within a range of $32.18 to $35.60.

Pharvaris N.V. (NASDAQ:PHVS) shares are flat -5.55% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Pharvaris N.V. trading at a premium to the broader market with a P/E of -10.1. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $33.49, suggesting 1.48% upside. Our AI forecast model points to short-term strength (4.48% over two weeks), a medium-term rise (32.67% over three months), and a longer-term gain (3.24% over one year), with expected trading ranges indicating moderate volatility.